StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research note issued to investors on Thursday morning. The firm issued a hold rating on the medical research company’s stock. Separately, HC Wainwright restated a neutral rating and set a $1.00 target price on shares of Cytosorbents in a report on Friday, […]
StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO – Free Report) in a research report released on Thursday morning. The brokerage issued a hold rating on the medical research company’s stock. Separately, HC Wainwright reaffirmed a neutral rating and set a $1.00 price target on shares of Cytosorbents in a research report on Friday, March […]
Cytosorbents (NASDAQ:CTSO – Get Free Report) and Modular Medical (NASDAQ:MODD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation. Institutional & Insider Ownership 34.2% of Cytosorbents shares […]
By Ben Glickman CytoSorbents said Thursday that a study of its surgical-bleeding treatment didn't meet its primary effectiveness endpoint in the overall.
Cytosorbents Co. (NASDAQ:CTSO – Get Free Report) Director Alan D. Sobel acquired 22,557 shares of Cytosorbents stock in a transaction on Wednesday, December 13th. The stock was purchased at an average cost of $1.33 per share, with a total value of $30,000.81. Following the completion of the transaction, the director now directly owns 101,857 shares […]